Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

R&D tax credit part of financial bailout bill

Executive Summary

A two-year extension of the R&D tax credit goes to the White House for President George Bush's signature as part of the Emergency Economic Stabilization Act that passed the House on Oct. 3 and the Senate on Oct. 1. Effective through the end of 2009, companies may take a credit of 20 percent of the amount by which their qualified research expenses in the taxable year exceed the base amount for that year. In addition, the alternative simplified credit is increased from 12 per cent to 14 percent for the 2009 tax year and the alternative incremental research credit is repealed for that period. The credit is estimated to be worth $19.1 billion to industry over 10 years

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel